S. 3738 · 115th Congress
Hatch-Waxman Integrity Act of 2018
- Stage
- In committee
- Sponsor
- Orrin Hatch
- Introduced
- 2018-12-11
- Latest action
- 2018-12-11 · Introduced in Senate
Summary
Hatch-Waxman Integrity Act of 2018
This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.